Ivan Kairatov brings a wealth of biopharma expertise to the table, standing at the intersection of molecular research and clinical innovation. His deep understanding of the “exposome”—the cumulative measure of environmental influences and associated biological responses throughout a lifetime—provides a unique lens through which to view the alarming rise of early-onset colorectal cancer. This disease, once considered a hallmark of aging, is increasingly claiming younger lives with a ferocity that traditional medicine struggles to explain. In this discussion, we explore the groundbreaking use of DNA methylation to decode decades of environmental exposure, the specific role of the herbicide picloram, and the molecular shifts that make these tumors so uniquely aggressive. By analyzing the intersection of lifestyle, socioeconomics, and chemical toxicity, Kairatov sheds light on a generational divide in cancer risk that demands a radical shift in public health policy.
DNA methylation is often viewed as a permanent molecular record. How do these epigenetic fingerprints allow for the reconstruction of a patient’s exposure history, and what are the primary difficulties in distinguishing between the impacts of herbicides, air pollution, and diet over several decades?
Think of DNA methylation as a molecular diary that our cells keep, recording every environmental “insult” we encounter. By looking at the irreversible attachment of methyl groups to specific sites on the DNA, we can see snapshots of a person’s life that were taken decades before their diagnosis. In this study, researchers leveraged Methylation Risk Scores to track 29 different factors, including 14 specific pesticides and various air pollutants like nitrogen dioxide. The challenge is that these signals are incredibly noisy; we have to sift through a lifetime of signals to find the one specific “fingerprint” left by a chemical like picloram. Because DNA methylation remains stable over time, it acts as a proxy for the exposome, allowing us to bridge the gap in historical data that usually thwarts long-term epidemiological studies.
Early-onset colorectal cancer often presents as more aggressive than cases in older adults. In what ways do the molecular profiles of these tumors differ regarding APC gene mutations, and how does the upregulation of Wnt/β-catenin signaling suggest a biologically distinct pathway for chemical-induced malignancies?
The biological “personality” of early-onset colorectal cancer is fundamentally different from what we see in patients over 70. In the older population, about 90% of tumors exhibit mutations in the APC gene, which is the classic pathway for this cancer. However, in younger patients, especially those with high exposure to picloram, that number drops to 74%, indicating that nearly a quarter of these cases are following a different rulebook. Instead of the typical APC-driven mutation, we see an upregulation of Wnt/β-catenin signaling in tumors with lower picloram exposure, suggesting that the herbicide may trigger a unique oncogenic process. This divergence is why these tumors are often more metastatic and aggressive at the time of diagnosis, as they aren’t following the “slow and steady” progression we’ve studied for decades.
Regional data suggests a correlation between picloram use intensity and cancer rates in people under age 50. How do you isolate the effects of a single herbicide from other environmental pollutants, and what metrics are most useful for determining the threshold where exposure becomes a significant clinical risk?
Isolating a single variable in a world full of chemicals is a massive undertaking, but the researchers utilized 21 years of population-level data from 94 US counties to draw these lines. By matching pesticide use intensity with local cancer incidence, they found a statistically significant link between picloram and early-onset disease, even after adjusting for socioeconomic variables and the use of other pesticides. The P-value for this association in the US county data was 4.52 × 10⁻⁴, which provides a very high level of statistical confidence. The most useful metric here is the Methylation Risk Score, which allows us to see how the intensity of use in a specific geography translates into a molecular signature within the patient’s own tissue.
Beyond chemical exposure, factors like educational attainment and dietary habits play a role in cancer risk. How should researchers weigh the cumulative effect of these lifestyle markers against environmental toxins, and what step-by-step methods can be used to identify high-risk individuals before symptoms appear?
It is a mistake to view lifestyle and environment as separate entities; they are deeply intertwined components of the exposome. For instance, the data showed that younger patients were significantly more likely to have epigenetic markers associated with lower educational attainment, with a P-value of 2.11 × 10⁻⁵, and a lower adherence to a Mediterranean diet. To identify high-risk individuals, we should first implement multi-phase screenings that look at these Methylation Risk Scores alongside traditional risk factors like smoking history and BMI. By analyzing these “fingerprints” in a discovery cohort and then validating them across independent cancer groups, as this study did with 83 young and 272 older patients, we can begin to build a predictive model. This step-by-step approach—moving from population data to molecular validation—allows us to catch the biological shifts long before a tumor actually forms.
Current screening and prevention strategies are largely based on data from older populations. How should environmental health policies evolve to address the unique risk factors found in younger patients, and what specific regulatory changes could most effectively mitigate the rising incidence of early-onset disease?
Our current policies are built on the “late-onset” model, which completely ignores the generational divide in environmental exposures. Since picloram has been widely used in the US since 1964, we are seeing a cumulative effect in younger generations that simply wasn’t as prevalent in their grandparents. Regulatory bodies need to move toward targeted environmental health policies that restrict the use of specific herbicides in areas with high incidence rates or rethink the “safe” levels of exposure for developing bodies. If we can adjust our screening age and focus on specific chemical markers, we can mitigate the surge of cases that are currently being caught far too late. We need a regulatory evolution that recognizes chemical exposure as a modifiable risk factor, much like we did with tobacco decades ago.
What is your forecast for early-onset colorectal cancer?
My forecast is that we are on the verge of a paradigm shift where colorectal cancer is no longer viewed as a disease of the elderly, but as a sentinel disease for environmental toxicity. As we refine our ability to read these epigenetic fingerprints, I expect we will discover that the surge in young patients is just the tip of the iceberg, driven by a cocktail of chemicals like picloram that have been accumulating in our environment for over 60 years. However, I am optimistic that by integrating Methylation Risk Scores into routine clinical practice, we can move from reactive treatment to proactive prevention. If we act now to reform agricultural regulations and start screening high-risk young adults by their 30s rather than their 50s, we can stall this trend and eventually see the incidence rates begin to plateau.
